U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H13N7S
Molecular Weight 359.408
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SGX-523

SMILES

CN1C=C(C=N1)C2=NN3C(SC4=CC=C5N=CC=CC5=C4)=NN=C3C=C2

InChI

InChIKey=BCZUAADEACICHN-UHFFFAOYSA-N
InChI=1S/C18H13N7S/c1-24-11-13(10-20-24)16-6-7-17-21-22-18(25(17)23-16)26-14-4-5-15-12(9-14)3-2-8-19-15/h2-11H,1H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22547164

SGX523 is a selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase. SGX523 was able to inhibit HGF-induced cell migration and cell scatter. SGX523 inhibition of MET in vivo was associated with the dose-dependent inhibition of growth of tumor xenografts derived from human glioblastoma and lung and gastric cancers. The clinical development of SGX523, however, was discontinued at Phase I due to renal toxicity manifested by an early rise of serum blood urea nitrogen and creatinine.

CNS Activity

Curator's Comment: Systemic delivery of SGX523 via oral gavage to mice bearing orthotopic human glioblastoma xenografts led to a significant decrease of in vivo tumor growth

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P08581
Gene ID: 4233.0
Gene Symbol: MET
Target Organism: Homo sapiens (Human)
2.7 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.
2010 Sep 1
Patents

Sample Use Guides

In a phase I clinical trials SGX523 was administered on an intermittent schedule at a starting dose of 60 mg PO BID for 14 days followed by 7 days of rest. The second protocol explored a continuous 28-day dosing schedule with SGX523 administered at a starting dose of 20 mg PO BID for 28 days without rest.
Route of Administration: Oral
To investigate cell migration, A549 cells were plated in 12-well plates (6 × 104 per well) and incubated to confluence. A channel was introduced into the monolayers by scratching with a pipette tip. Various dilutions of the compound were added in starve medium in the presence and absence of HGF (90 ng/mL). Twenty-four hours later, wells were checked for cell migration. Cells were stained and visualized. SGX523 was active in prevention cells migration at concentrations above 50 nM
Name Type Language
SGX-523
Code English
QUINOLINE, 6-((6-(1-METHYL-1H-PYRAZOL-4-YL)-1,2,4-TRIAZOLO(4,3-B)PYRIDAZIN-3-YL)THIO)-
Systematic Name English
SGX523
Code English
Code System Code Type Description
CAS
1022150-57-7
Created by admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
PRIMARY
CHEBI
90624
Created by admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
PRIMARY
FDA UNII
WH8SQN09KJ
Created by admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
PRIMARY
ChEMBL
CHEMBL1236107
Created by admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
PRIMARY
EPA CompTox
DTXSID70647300
Created by admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
PRIMARY
DRUG BANK
DB06314
Created by admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
PRIMARY
NCI_THESAURUS
C74062
Created by admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
PRIMARY
PUBCHEM
24779724
Created by admin on Sat Dec 16 08:24:38 GMT 2023 , Edited by admin on Sat Dec 16 08:24:38 GMT 2023
PRIMARY